People on the Move
Scholar Rock
Scholar Rock, a biopharma company developing niche modulators that selectively target growth factor activation in the disease microenvironment, has appointed Gregory Carven VP of Antibody Discovery and Protein Sciences.
Carven has more than 15 years of antibody discovery and development experience, including as co-inventor of Keytruda (pembrolizumab), the first PD-1 inhibitor for cancer immunotherapy to receive FDA approval.
In his role at Scholar Rock, he will direct the company’s design of therapeutic antibodies as first-in-class niche modulators for fibrotic, musculoskeletal and autoimmune diseases.
Most recently, Carven was head of hybridoma research within Pfizer’s Global Biotherapeutics Technologies division and was responsible for discovery and engineering antibodies and antibody binding domains for a wide variety of therapeutic areas.
Before Pfizer, he held positions of increasing responsibility at Merck Research Laboratories and Phylogix, Inc.
